Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

When the FT-T2D was used, 16 of 55 patients (25%; 95% CI 15–39) had score of at least 0.60, the cutoff chosen for eF, which decreased to 12 patients (22%; 95% CI 12–35) without significant fibrosis (FT-T2D < 0.60, Figure 1 C), a highly significant decrease (Nam RMLE-Score = 14.3; p = 0.0002).

also in 132,142 other papers